Rucaparib Tied To Longer Quality-Adjusted PFS And Time Without Symptoms Or Toxicity In Women With Recurrent Ovarian Cancer Compared To Placebo

The Journal of Clinical Pathways (11/10, Tumolo) reports researchers found “quality-adjusted progression-free survival (PFS) and time without symptoms or toxicity in women with recurrent ovarian cancer were longer with rucaparib compared with placebo.” The findings were published in the Journal of Clinical Oncology.